Leap Therapeutics Inc./$LPTX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
Ticker
$LPTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
26
ISIN
US52187K2006
Website
LPTX Metrics
BasicAdvanced
$12M
-
-$1.69
-0.22
-
Price and volume
Market cap
$12M
Beta
-0.22
52-week high
$0.65
52-week low
$0.22
Average daily volume
2.3M
Financial strength
Current ratio
2.413
Quick ratio
2.381
Total debt to equity
0.739
Interest coverage (TTM)
-11,890.00%
Profitability
EBITDA (TTM)
-71.339
Effective tax rate (TTM)
-0.85%
Management effectiveness
Return on assets (TTM)
-96.05%
Return on equity (TTM)
-203.49%
Valuation
Price to book
0.58
Price to tangible book (TTM)
0.58
Price to free cash flow (TTM)
-0.202
Free cash flow yield (TTM)
-494.66%
Free cash flow per share (TTM)
-144.14%
Growth
Earnings per share change (TTM)
-23.95%
3-year earnings per share growth (CAGR)
-27.26%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Leap Therapeutics Inc. stock?
Leap Therapeutics Inc. (LPTX) has a market cap of $12M as of July 06, 2025.
What is the P/E ratio for Leap Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Leap Therapeutics Inc. (LPTX) stock is 0 as of July 06, 2025.
Does Leap Therapeutics Inc. stock pay dividends?
No, Leap Therapeutics Inc. (LPTX) stock does not pay dividends to its shareholders as of July 06, 2025.
When is the next Leap Therapeutics Inc. dividend payment date?
Leap Therapeutics Inc. (LPTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Leap Therapeutics Inc.?
Leap Therapeutics Inc. (LPTX) has a beta rating of -0.22. This means that it has an inverse relation to market volatility.